The UK regulator suspended Amgen's drug Tavneos for new patients due to unreliable data, following similar EU actions and a proposed US FDA withdrawal. Existing patients may continue treatment for six
Amgen reported a data breach affecting patient health information and potentially R&D data stored on third-party cloud systems. While manufacturing operations are unaffected, the company is assessing
Amgen agreed to a $74 million settlement regarding a shareholder lawsuit alleging concealment of a $10.7 billion tax liability tied to its Puerto Rico drug manufacturing operations. The company denies
A federal judge blocked Colorado's price cap on Amgen's arthritis drug Enbrel, ruling it violated federal patent law and threatened irreparable harm. The injunction preserves Amgen's pricing strategy
ChemBrief